FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPI	ROVAL
OMB Number:	3235-0287
Estimated average	burden
houre par raenones	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Lobacki Joseph M (Last) (First) (Middle) C/O SUTRO BIOPHARMA, INC., 310 UTAH AVENUE, SUITE 150 (Street) SOUTH SAN FRANCISCO, CA 94080			2. Issuer Name and Ticker or Trading Symbol SUTRO BIOPHARMA, INC. [STRO]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner						
			1 ′ /	3. Date of Earliest Transaction (Month/Day/Year) 06/05/2020					Officer (give title below) Other (specify below)					
			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person				e)	
(Cit		(State)	(Zip)	Table I - Non-Derivative Securities Acqu				s Acquired,	lired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	any	emed on Date, if /Day/Year		. 8) (1	A) or Disposed of instr. 3, 4 and 5) (A) or (D) (A) or (D)	of (D) Own Tran		Securities Being Reported	d (Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder:	Report on a s	eparate line for each	class of securities b	peneficial	lly owned	irectiy	Person	s who respon					ed SEC	474 (9-02)
Reminder:	Report on a s	eparate line for each	Table II -	Derivati	ve Securi	ies Acc	Person in this t display	s who respon form are not re s a currently v osed of, or Bene	equired to valid OMB	respond control r	unless the		ed SEC	474 (9-02)
1. Title of		3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., put 4. Transaci Code	ve Securities, calls, we stion of De Securi	mber rivative (ties red (A) posed	Person in this i display quired, Dispos, options, co 6. Date Exe Expiration (Month/Day	s who respon form are not re s a currently vessed of, or Bene nvertible securer creisable and Date	equired to valid OMB	respond control r ned I Amount ing	unless the number.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivativ Security: Direct (I or Indire s) (I)	11. Natur of Indired Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., put 4. Transaci Code	ve Securits, calls, w 5. Nu 5. Nu Secur Acqu or Di: of (D (Instr	ies Accarrants mber rivative ities red (A) posed	Person in this 1 display quired, Dispos, options, co 6. Date Exe Expiration (Month/Day	s who respon form are not re s a currently v sed of, or Bene nvertible secur recisable and Date y/Year) Expiration	required to valid OMB ficially Ownities) 7. Title and of Underlying Securities	respond control r ned I Amount ing	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported	f 10. Ownersh Form of Derivativ Security: Direct (I or Indire	11. Natur of Indire- Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Lobacki Joseph M C/O SUTRO BIOPHARMA, INC. 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO, CA 94080	X				

Signatures

/s/ Edward C. Albini as attorney-in-fact	06/08/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is fully vested on June 5, 2021, subject to the reporting person's provision of service to the issuer on the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.